Company

XNApharma started as "BianoScience", which was founded as a spin-off from the Friedrich-Schiller-University Jena, Germany, in 2011 as a privately owned biotech company. Our focus has been on oligonucleotides ever since. We developed a Peptide-siRNA-Produg platform, which consists of a chimeric siRNA deactivated by a peptide cap. Disease-specific proteases cleaving off the peptide activate the siRNA selectively in diseased tissue or cells. Applications of the this platform include anticancer and antiviral therapies.
Stepping into late-preclinical phase, we required gramm-scale amounts of GMP material, which was hard to get on the market at that time.

For this reason, in 2017, we founded BianoGMP which is focused on small scale GMP-oligonucleotide services. We moved to Gera, installed cleanrooms, synthesizer, and downstream processes. During this time BianoGMP greatly appreciated funding obtained from the European Regional Development Fund and the state of Thuringia enabling us to increase our quality, receive a GMP certificate, and access the market. Since 2020, we are supplying customers all over the world with GMP oligonucleotides for initial clinical trials.

In 2023, BianoGMP was acquired by EUROAPI – a specialist in large scale oligonucleotide and other API-production. In this partnership, BianoGMP gained larger production capabilities, installed new cleanrooms, large-scale synthesizers and downstream process in order to provide larger batch sizes and support customers stepping into later clinical development.

In 2024, BianoScience was converted into XNApharma. This marks the beginning of its new therapeutic development based on the Peptide-siRNA-Prodrug technology platform and on the experiences we made during the last 15 years. The whole therapeutic concept was re-evaluated and now we are preparing the next steps into clinical development.